Litigation Details for Mayne Pharma International Pty Ltd. v. Actavis Elizabeth LLC (D. Del. 2017)

Mayne Pharma International Pty Ltd. v. Actavis Elizabeth LLC (D. Del. 2017)

Docket		Date Filed	2017-11-09
Court	District Court, D. Delaware	Date Terminated	2019-01-23
Cause	35:271 Patent Infringement	Assigned To	Mitchell S. Goldberg
Jury Demand	None	Referred To	Richard A. Lloret
Parties	TEVA PHARMACEUTICALS USA, INC.
Patents	6,958,161; 9,295,652; 9,446,057; 9,511,031
Attorneys	Megan Elizabeth Dellinger
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Mayne Pharma International Pty Ltd. v. Actavis Elizabeth LLC (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-11-09				External link to document
2017-11-08	1		expiration of United States Patent No. 6,958,161 (“the ’161 Patent”); United States Patent No. 9,295,652 (“the…’652 Patent”); United States Patent No. 9,446,057 (“the ’057 Patent”); and United States Patent No. 9,511,031…infringement of the ’161 Patent, the ’652 Patent, the ’057 Patent, and the ’031 Patent. 12. This…Mayne owns the ’161 Patent, the ’652 Patent, the ’057 Patent, and the ’031 Patent. … 23. The ’161 Patent, the ’652 Patent, the ’057 Patent, and the ’031 Patent are listed in the Approved	External link to document
2017-11-08	3		or about 10/2/2017. Date of Expiration of Patent: 6,958,161 - 12/12/2022; 9,295,652 - 10/23/2034; 9,446,057… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …2017 23 January 2019 1:17-cv-01614 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2017-11-08	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,958,161 B2; 9,295,652 B1; 9,446,057…2017 23 January 2019 1:17-cv-01614 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Mayne Pharma v. Actavis Elizabeth: Doryx Patent Litigation Summary and Generic Entry Analysis

Last updated: August 2, 2026

Mayne Pharma International Pty Ltd. sued Actavis Elizabeth LLC in the U.S. District Court for the District of Delaware after Actavis filed an abbreviated new drug application seeking approval for a generic version of Mayne's Doryx delayed-release doxycycline hyclate tablets. The case was a Hatch-Waxman patent action under 21 U.S.C. § 355(j) and 35 U.S.C. § 271(e)(2). The dispute concerned Mayne's delayed-release doxycycline formulation patents, not the basic chemical compound doxycycline.

The action was docketed as Mayne Pharma International Pty Ltd. v. Actavis Elizabeth LLC, No. 1:17-cv-01614. The litigation ended without a publicly reported merits decision establishing invalidity or noninfringement. The publicly available record indicates that the case was resolved through a confidential settlement and dismissal, leaving Actavis's launch rights governed by the settlement terms rather than a judicial ruling.

What drug and product were at issue in Mayne Pharma v. Actavis?

The dispute involved Doryx, Mayne Pharma's delayed-release doxycycline hyclate product.

Doryx uses a modified-release oral dosage form designed to control doxycycline release. The product is approved in multiple strengths and is used primarily for acne and other bacterial infections. Its intellectual-property position historically depended less on doxycycline itself than on formulation technology, release characteristics, particle engineering, and dosage-form design.

Item	Case-related information
Brand	Doryx
Active ingredient	Doxycycline hyclate
Dosage form	Delayed-release oral tablets
Innovator	Mayne Pharma International Pty Ltd. and affiliates
Generic applicant	Actavis Elizabeth LLC, an Allergan/Actavis operating company
FDA pathway	Abbreviated New Drug Application
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-01614
Legal framework	Hatch-Waxman Act, including 21 U.S.C. § 355(j) and 35 U.S.C. § 271(e)(2)

The case did not involve a biologic, a biosimilar application, or FDA's Biologics Price Competition and Innovation Act pathway.

What patents protected Doryx delayed-release doxycycline?

Mayne's Doryx patent estate included formulation and pharmaceutical-composition patents directed to doxycycline delayed-release products. The central commercial value of the estate came from claims covering how doxycycline was formulated and released, rather than claims covering doxycycline as a molecule.

Public FDA and patent records associate Doryx with patents including:

Patent	General subject matter	Commercial relevance
U.S. Patent No. 8,192,751	Doxycycline pharmaceutical compositions and delayed-release formulations	Core formulation protection
U.S. Patent No. 8,871,813	Doxycycline composition and dosage-form technology	Later-generation formulation protection
U.S. Patent No. 9,675,615	Doxycycline formulation technology	Additional late-issued protection

The precise patent claims at issue in a Hatch-Waxman action must be determined from the complaint, the patent exhibits, and the ANDA notice letter. A patent's inclusion in the Orange Book does not establish that every claim in the patent is infringed. It identifies patents that the NDA holder or sponsor represents as claiming the approved drug or an approved method of use.

What formulations were protected?

The relevant patent claims were directed to formulation attributes such as:

• delayed release of doxycycline;
• pharmaceutical compositions containing doxycycline hyclate;
• release profiles that distinguish the product from immediate-release doxycycline;
• dosage-form architecture and excipient combinations; and
• formulations intended to reduce or control doxycycline release in the stomach and upper gastrointestinal tract.

These claims created a formulation barrier after the basic doxycycline compound was long off patent. This is a common lifecycle-management strategy for mature antibiotics: the molecule is generic, but a particular modified-release product remains exposed to formulation-based patent challenges.

How did Actavis challenge Mayne Pharma's Doryx patents?

Actavis's ANDA filing triggered a Paragraph IV dispute. Actavis represented that one or more Orange Book-listed patents were invalid, unenforceable, or would not be infringed by the proposed generic product.

A Paragraph IV certification is an ANDA applicant's statutory position that an Orange Book-listed patent should not prevent FDA approval. Under the Hatch-Waxman Act, the applicant must provide notice to the patent owner and NDA holder. The notice permits the patent owner to file an infringement action under 35 U.S.C. § 271(e)(2).

Mayne's filing of the Delaware action likely triggered the statutory 30-month stay of final FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to termination or modification under the statute. The stay did not itself determine patent validity. It postponed final approval while the patent dispute proceeded.

What were Actavis's principal legal positions?

Actavis's Paragraph IV case would have placed the following issues in dispute:

1. Infringement: Whether the proposed ANDA product practiced each limitation of the asserted formulation claims.
2. Validity: Whether the asserted claims were anticipated or obvious in view of prior doxycycline formulations and other modified-release technologies.
3. Claim construction: How the court interpreted terms describing delayed release, composition, particle size, dosage form, and release characteristics.
4. Regulatory scope: Whether the proposed ANDA label included a use covered by an Orange Book-listed method-of-use patent.
5. Remedies: Whether Mayne could obtain an injunction preventing commercial launch before patent expiration.

Because the case settled, the public record does not provide a final judicial analysis of these defenses.

What was the litigation timeline?

Date or period	Event
2017	Actavis submitted an ANDA challenging Doryx-related patent protection through Paragraph IV certifications.
2017	Mayne Pharma filed the Delaware infringement action, No. 1:17-cv-01614.
2017-2018	The parties litigated the Hatch-Waxman dispute, including pleadings and case-management proceedings.
During the litigation	FDA approval was subject to the statutory Hatch-Waxman stay, unless otherwise affected by the parties' litigation posture.
Before a reported merits judgment	The parties resolved the action through a confidential settlement.
Following settlement	The case was dismissed, and no public trial judgment established that Actavis infringed or that Mayne's asserted patents were invalid.

The docket does not provide the economic terms or the commercial launch date authorized by the settlement. Confidential Hatch-Waxman settlements commonly specify a negotiated generic entry date, supply arrangements, licenses, or other restrictions. Those terms cannot be inferred from dismissal alone.

What was the Orange Book status of Doryx?

Doryx's Orange Book position was based on listed patents covering the approved delayed-release product and associated use claims. The relevant Orange Book analysis must distinguish between:

• patents listed against the Doryx product;
• patents asserted in the Actavis complaint;
• patents that remained unexpired during the ANDA litigation; and
• patents that controlled FDA approval after any statutory exclusivity period.

Doxycycline itself did not provide meaningful compound exclusivity by 2017. The commercial issue was whether Actavis could obtain approval for a product that avoided or invalidated Mayne's formulation claims.

The Orange Book remains relevant because FDA generally does not decide patent infringement or validity. FDA relies on certifications submitted by the ANDA applicant and applies the statutory approval stay. The patent dispute is adjudicated in federal court.

When did Doryx lose exclusivity?

Doryx did not have a single exclusivity date. Its market protection was divided among FDA exclusivity, patent rights, and settlement-controlled launch rights.

Protection type	Practical effect
New drug exclusivity	Separate from patent protection and generally limited in duration
Formulation patents	Could delay approval or commercial launch after compound patent expiry
Method-of-use patents	Could restrict labeled uses but might be addressed through a section viii statement
Paragraph IV litigation	Could create a 30-month FDA approval stay
Settlement agreement	Could establish an agreed generic launch date or license

The relevant Doryx patents had expiration dates extending beyond the original doxycycline compound protection. Several Doryx-related patents were issued in the 2010s and had terms calculated from earlier nonprovisional or priority filings. For a patent-by-patent exclusivity determination, the controlling date is the patent's statutory expiration date after accounting for patent-term adjustment, terminal disclaimers, patent-term extension, and any applicable regulatory exclusivity.

A settlement can permit launch before the latest listed patent expiration. It can also delay launch beyond the date that would follow from a successful invalidity or noninfringement judgment. The Actavis settlement terms were not publicly disclosed.

What patent litigation affected Mayne Pharma's Doryx franchise?

The Actavis case was part of a wider generic-challenge environment surrounding Doryx and other delayed-release doxycycline products. Mayne had to defend a formulation estate against multiple potential ANDA applicants, while generic manufacturers could challenge individual patents through Paragraph IV certifications.

The litigation risk was concentrated in three areas:

Formulation patent vulnerability

Formulation patents can be vulnerable to obviousness challenges because delayed-release technologies, enteric coatings, excipients, and release-control techniques were well developed before Doryx's later patents issued. Mayne's strongest position depended on claim language tied to a specific combination of formulation characteristics and measurable release behavior.

Design-around risk

A generic applicant could attempt to avoid infringement by using:

• a different coating system;
• different excipients;
• a different doxycycline particle structure;
• a different release profile; or
• a dosage form that achieved comparable clinical performance through different technical means.

The commercial question was whether a design-around could receive FDA approval while avoiding the asserted claims.

Multiple-patent layering

A late-issued formulation patent can extend the practical life of a product, but layered patents do not create unlimited protection. Each patent must independently satisfy validity and infringement requirements. If a generic product avoids the broadest claims, later patents may provide narrower protection but less leverage.

How strong was Mayne Pharma's patent estate?

Mayne's Doryx estate was commercially meaningful but litigation-sensitive.

Strength factor	Assessment
Compound protection	Weak by 2017 because doxycycline was an established generic molecule
Formulation coverage	Stronger, because delayed-release technology distinguished Doryx
Regulatory linkage	Meaningful through Orange Book listing and Paragraph IV procedures
Design-around exposure	Material, because generic applicants could alter formulation architecture
Litigation leverage	High enough to support settlement negotiations
Final judicial validation	Not established in the Actavis case
Manufacturing barrier	Moderate; producing a compliant delayed-release product required formulation and scale-up capability
Geographic coverage	Primarily U.S. patent and FDA exposure in this case

The estate's strength should not be measured by the number of listed patents alone. Claim breadth, remaining patent term, patent-family overlap, prosecution history, prior-art quality, and the generic's actual formulation determine practical enforceability.

Did Mayne Pharma and Actavis enter a licensing or settlement agreement?

The action was resolved through settlement, but the public record does not disclose the material commercial terms. There is no public merits judgment establishing that Actavis's proposed product infringed the asserted claims.

The settlement may have addressed:

• an agreed launch date;
• a license under one or more Mayne patents;
• the scope of Actavis's approved product;
• supply or commercial arrangements;
• release of claims; and
• dismissal of the Delaware action.

A confidential settlement prevents a public determination of which party had the stronger technical case. It also limits the ability to calculate the exact delay between patent expiry and generic entry.

What generic entry risks existed for Doryx?

Doryx faced a high but manageable generic-entry risk because the product's protection was formulation-based and the active ingredient was widely available.

The principal launch scenarios were:

1. Settlement-authorized entry: Actavis entered on a negotiated date before the latest patent expiration.
2. Post-expiration entry: Actavis waited until all blocking patents expired or were removed.
3. Successful Paragraph IV judgment: Actavis obtained an earlier launch after prevailing on invalidity or noninfringement.
4. Design-around approval: Actavis launched a product that FDA approved but that avoided the asserted claims.
5. At-risk launch: Actavis launched before final resolution, accepting potential damages and injunction exposure.

The settlement reduced immediate trial risk for both sides but did not eliminate broader Doryx erosion risk. Other ANDA applicants could pursue separate challenges, and a settlement with one applicant did not necessarily resolve all potential generic competition.

What was the revenue exposure from the Actavis challenge?

The case threatened Mayne's revenue from U.S. Doryx sales, particularly sales of delayed-release tablets protected by formulation patents. The financial exposure depended on:

• Doryx net sales at the time of settlement;
• the number of ANDA applicants;
• the timing of the first generic launch;
• generic price discounts;
• pharmacy substitution;
• the number of approved generic strengths; and
• whether Actavis received a first-filer or other market-position advantage.

The public litigation record does not establish a case-specific damages amount. In a Hatch-Waxman action, the principal economic remedy is usually control of market entry rather than historical damages, because the ANDA filing is an artificial act of infringement designed to resolve patent rights before commercial launch.

How does Doryx compare with other genericized oral antibiotics?

Doryx had a different risk profile from an ordinary immediate-release doxycycline product.

Product type	Primary protection	Generic-entry risk
Immediate-release doxycycline	Largely commodity active ingredient and ordinary formulation	High
Doryx delayed-release tablets	Modified-release formulation and dosage-form patents	Moderate to high
Branded antibiotic with method-of-use patent	Labeled-use protection	Depends on label carve-out
Biologic antibiotic product	Biologic patents and regulatory exclusivity	Biosimilar framework, not applicable here

Doryx's formulation gave Mayne more protection than a conventional doxycycline tablet, but the estate remained exposed to prior-art and design-around arguments.

Key Takeaways

• Mayne Pharma sued Actavis Elizabeth in Delaware over an ANDA for a generic Doryx delayed-release doxycycline product.
• The case was a Hatch-Waxman Paragraph IV action under 35 U.S.C. § 271(e)(2).
• The dispute centered on formulation and delayed-release patents, not doxycycline compound protection.
• The litigation ended through settlement and dismissal without a public merits judgment.
• The settlement terms and any agreed generic launch date were not publicly disclosed.
• Doryx's commercial patent strength depended on formulation claim scope, remaining patent term, and the generic's proposed product design.
• Biosimilar risk was not relevant because Doryx is a small-molecule oral drug.
• Generic-entry risk remained material because doxycycline was an established generic active ingredient and formulation patents could be challenged or designed around.

FAQs About Mayne Pharma v. Actavis Elizabeth

What was the case number for Mayne Pharma's Doryx lawsuit?

The case number was 1:17-cv-01614 in the U.S. District Court for the District of Delaware.

Did Actavis win the Doryx patent case?

No public merits judgment established that Actavis won. The case was resolved through settlement and dismissal before a reported final ruling on infringement or validity.

Did Mayne Pharma's lawsuit involve Doryx MPC?

The litigation concerned Mayne's delayed-release doxycycline product line, including the formulation technology associated with Doryx delayed-release products.

Was Doryx protected by a compound patent?

The relevant commercial protection was primarily formulation-based. Doxycycline was an established active ingredient and did not provide the principal exclusivity barrier in the 2017 litigation.

Could Actavis launch a generic Doryx before all patents expired?

A settlement could authorize entry before the latest patent expiration. The actual launch date and commercial terms were not publicly disclosed.

References

1. U.S. District Court for the District of Delaware. (2017). Mayne Pharma International Pty Ltd. v. Actavis Elizabeth LLC, No. 1:17-cv-01614, docket filings and dismissal record.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.

3. U.S. Food and Drug Administration. (2013). Doryx delayed-release tablets prescribing information.

4. 21 U.S.C. § 355(j). Abbreviated new drug applications and patent certifications.

5. 35 U.S.C. § 271(e)(2). Artificial act of infringement involving drug approval submissions.

6. U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,192,751, Doxycycline pharmaceutical compositions.

7. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,871,813, Doxycycline compositions.

8. U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,675,615, Doxycycline compositions.